Clinical observation of Wumeiwan combined with triple therapy for treatment of chronic atrophic gastritis
10.3760/cma.j.issn.1673-4246.2018.08.005
- VernacularTitle: 乌梅丸联合三联疗法治疗慢性萎缩性胃炎临床研究
- Author:
Yinping MA
1
;
Xiufang JIN
;
Fengchao XU
;
Mingyan CHEN
Author Information
1. Department of Pharmacy, Pinggu Hospital of Beijing Chinese Medicine Hospital, Beijing 101200, China
- Publication Type:Journal Article
- Keywords:
Gastritis, atrophic;
Wu Mei Wan;
Triple therapy;
Efficacy;
Safety
- From:
International Journal of Traditional Chinese Medicine
2018;40(8):702-705
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore clinical efficacy and safety of Wumeiwan combined with triple therapy for treatment of chronic atrophic gastritis (CAG).
Methods:According to the random indicator method, 113 patients with CAG were divided into control group (n=56) and treatment group (n=57). Patients of control group were treated with triple therapy, while treatment groupwere treated Wumeiwan combined with triple therapy. The two groups were treated for 3 months. Clinical effect was evaluated after treatment. The helicobacter pylori (Hp) conversion to negative of the two groups was compared and recorded. The Hp overcast conditions of the two groups were compared. The serum TNF-α, IL-6, IL-8 and peripheral blood CD3+, CD4+, CD8+, CD4+/CD8+ of the two groups before and after treatment were compared. The adverse reactions of the two groups during the treatment were compared.
Results:Total effective rate of treatment group was 94.7% (54/57), which was significantly higher than the control group 82.14% (46/56), and the difference was statistically significant (χ2=4.401, P=0.036). Hp overcast rate of treatment group was 88.2% (45/51), which was significantly higher than the control group 48.0%(24/50), and the difference was statistically significant (χ2=18.883, P=0.000). After treatment, the serum TNF-α (1.43 ± 0.17 mg/L vs. 1.97 ± 0.22 mg/L, t=14.615), IL-6 (30.79 ± 3.65 ng/L vs. 41.13 ± 4.10 ng/L, t=14.166), IL-8 (7.52 ± 1.32 ng/L vs. 9.60 ± 1.77 ng/L, t=7.090) in the treatment group were lower than those in the control group (P<0.05). After treatment, the peripheral blood CD3+ (75.12% ± 16.44% vs. 67.33% ± 14.37%, t=2.680), CD4+ (39.02% ± 11.41% vs. 33.49% ± 10.61%, t=2.667), CD4+/CD8+ (1.58 ± 0.35 vs. 1.19 ± 0.32, t=6.179) in the treatment group were higher than those in the control group (P<0.05), the peripheral blood CD8+ (24.75% ± 9.69% vs. 28.12% ± 11.29%, t=1.704) in the treatment group were higher than those in the control group (P<0.05). There was no significantly difference of the adverse reaction rates of the two groups during treatment (χ2=0.134, P=0.714).
Conclusions:The Wumeiwan combined with triple therapy for treatment of CAG has a good efficacy and low adverse reactions, has serious anti-inflammatory effects, can improve the body immunity, and it was worthy clinical application.
